Some biotech companies fear that they will be linked to big pharmaceutical companies (Big Pharma). These biotechs are creating a new industry group as a hedge against President Trump's policies. President Trump appreciates price deals with the pharmaceutical industry, and major drug manufacturers are participating in the TrumpRx platform. Biotech firms feel left out of these deals. Nearly a dozen mid-sized biotech companies have formed the Midsized Biotech Alliance of America (MBAA). MBAA members have one or two drugs on the market and focus on policies affecting commercially available drugs. Unlike the startups in the BIO group, they do not have extensive drug portfolios, which makes them less flexible on pricing. The aim is to ensure that biotechs are not disproportionately affected when prices are reduced to the levels of other countries.[3]